Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke

NCT05295173 is registered in ClinicalTrials.gov with Angde Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05295173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke
Lead sponsor
Angde Biotech Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 21, 2022
Completion date
June 22, 2023
Enrollment
1,412 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke